Target Information
| Target General Information | Top | |||||
|---|---|---|---|---|---|---|
| Target ID |
T61484
(Former ID: TTDI01946)
|
|||||
| Target Name |
Chymotrypsin (CTR)
|
|||||
| Gene Name |
NO-GeName
|
|||||
| Target Type |
Clinical trial target
|
[1] | ||||
| Disease | [+] 4 Target-related Diseases | + | ||||
| 1 | Pancreatic malfunction [ICD-11: DC30-DC3Z] | |||||
| 2 | Attention deficit hyperactivity disorder [ICD-11: 6A05] | |||||
| 3 | Autism spectrum disorder [ICD-11: 6A02] | |||||
| 4 | Cystic fibrosis [ICD-11: CA25] | |||||
| BioChemical Class |
Peptidase
|
|||||
| UniProt ID | ||||||
| Drugs and Modes of Action | Top | |||||
|---|---|---|---|---|---|---|
| Clinical Trial Drug(s) | [+] 3 Clinical Trial Drugs | + | ||||
| 1 | Pancrecarb | Drug Info | NDA filed | Pancreatic malfunction | [2] | |
| 2 | CM-AT | Drug Info | Phase 3 | Autism spectrum disorder | [3] | |
| 3 | Liprotamase | Drug Info | Phase 3 | Cystic fibrosis | [4] | |
| Mode of Action | [+] 1 Modes of Action | + | ||||
| Modulator | [+] 5 Modulator drugs | + | ||||
| 1 | Pancrecarb | Drug Info | [1], [5] | |||
| 2 | CM-AT | Drug Info | [6] | |||
| 3 | Liprotamase | Drug Info | [7] | |||
| 4 | JBP-1 | Drug Info | [1], [5] | |||
| 5 | POP-1 | Drug Info | [1], [5] | |||
| Target Poor or Non Binders | Top | |||||
|---|---|---|---|---|---|---|
| Target Poor or Non Binders | ||||||
| References | Top | |||||
|---|---|---|---|---|---|---|
| REF 1 | US patent application no. 2012,0251,516, PHARMACEUTICAL COMPOSITION FOR TREATING CANCER COMPRISING TRYPSINOGEN AND/OR CHYMOTRYPSINOGEN AND AN ACTIVE AGENT SELECTED FROM A SELENIUM COMPOUND, A VANILLOID COMPOUND AND A CYTOPLASMIC GLYCOLYSIS REDUCTION AGENT. | |||||
| REF 2 | Clinical pipeline report, company report or official report of Digestive Care. | |||||
| REF 3 | ClinicalTrials.gov (NCT00881452) A Trial of CM-AT in Children With Autism. U.S. National Institutes of Health. | |||||
| REF 4 | ClinicalTrials.gov (NCT00500084) Phase III ALTU-135 CP Safety Trial. U.S. National Institutes of Health. | |||||
| REF 5 | EP patent application no. 2490711, A pharmaceutical composition for treating cancer comprising trypsinogen and/or chymotrypsinogen and an active agent selected from a selenium compound, a vanilloid compound and a cytoplasmic glycolysis reduction agent). | |||||
| REF 6 | Drugmakers dance with autism. Nat Biotechnol. 2010 Aug;28(8):772-4. | |||||
| REF 7 | Clinical pipeline report, company report or official report of Anthera Pharmaceuticals. | |||||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.